These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3709959)

  • 41. Susceptibility of Actinobacillus actinomycetemcomitans strains to norfloxacin.
    Avila-Campos MJ; Mol-Resende C; Carvalho MA; Damasceno CA; Cisalpino EO
    Braz Dent J; 1995; 6(1):29-32. PubMed ID: 8688646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
    Digranes A; Dibb WL; Benonisen E
    Chemotherapy; 1985; 31(6):466-71. PubMed ID: 2934234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prevalence of qnr genes in clinical Enterobacteriaceae non-susceptible to fluoroquinolone in Poland].
    Piekarska K; Rzeczkowska M; Zacharczuk K; Chróst A; Januszkiewicz A; Bareja E; Olak M; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(3):211-9. PubMed ID: 23285775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [In vitro comparative activity of norfloxacin in the comparison of pathogenic bacteria of the urinary tract].
    Carlone NA; Cuffini AM; Tullio V; Savoia D; Cavallo GP
    G Batteriol Virol Immunol; 1986; 79(1-6):85-97. PubMed ID: 3479370
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
    Edwards R; Kanematsu M; Greenwood D
    J Antimicrob Chemother; 1988 Dec; 22(6):885-90. PubMed ID: 3243736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. False-resistance of Streptococcus faecalis and Pseudomonas maltophilia to norfloxacin by disc diffusion susceptibility testing.
    Grimard D; Bergeron MG
    J Antimicrob Chemother; 1985 Jul; 16(1):132-3. PubMed ID: 3930460
    [No Abstract]   [Full Text] [Related]  

  • 48. Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.
    Paganoni R; Herzog C; Braunsteiner A; Hohl P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():3-17. PubMed ID: 3144545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Activity of cefotaxime and ceftriaxone and of imipenem, pefloxacin and norfloxacin on 13 species of bacteria].
    Rahal K
    Arch Inst Pasteur Alger; 1989; 57():213-48. PubMed ID: 2489401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Effect of norfloxacin in infections of the urinary and intestinal tracts: combined effects with aminoglucosides and with tetracycline and chloramphenicol].
    Mascellino MT; Lorenzi A; Bonanni M; Iegri F
    G Ital Chemioter; 1985; 32(2):497-500. PubMed ID: 3833594
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative aspects of the diffusion of norfloxacin, cefepime and spermine through the F porin channel of Enterobacter cloacae.
    Chevalier J; Malléa M; Pagès JM
    Biochem J; 2000 May; 348 Pt 1(Pt 1):223-7. PubMed ID: 10794735
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites.
    Corradi F; Brusasco C; Fernández J; Vila J; Ramirez MJ; Seva-Pereira T; Fernández-Varo G; Mosbah IB; Acevedo J; Silva A; Rocco PR; Pelosi P; Gines P; Navasa M
    Dig Liver Dis; 2012 Mar; 44(3):239-44. PubMed ID: 22119621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Bacteriostatic effects of silver norfloxacin, silver sulfadiazine, and "moisture burn ointment"].
    Liao WZ
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1993 May; 9(3):184-5. PubMed ID: 8402351
    [No Abstract]   [Full Text] [Related]  

  • 55. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent.
    Wolfson JS; Hooper DC
    Ann Intern Med; 1988 Feb; 108(2):238-51. PubMed ID: 3277508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The comparative in-vitro activity of pefloxacin.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy of norfloxacin in the treatment of urinary tract infections in Tikure Anbessa Hospital, Addis Ababa, Ethiopia.
    Mengesha B
    East Afr Med J; 1991 Nov; 68(11):844-52. PubMed ID: 1800077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amino acid norfloxacin derivatives as prodrugs.
    Hribar-Kikelj A; Fercej-Temeljotov D; Zmitek J
    Pharmazie; 1993 Jan; 48(1):64-5. PubMed ID: 8460176
    [No Abstract]   [Full Text] [Related]  

  • 59. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics.
    Debbia E; Schito GC; Nicoletti G; Speciale A
    Chemioterapia; 1987 Oct; 6(5):319-23. PubMed ID: 3480779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The effect of subinhibitory concentrations of norfloxacin, erythromycin and roxithromycin on Pseudomonas aeruginosa virulence factors].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1995 Sep; 44(3):115-7. PubMed ID: 7489133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.